4.7 Article

Effects of colon-targeted vitamins on the composition and metabolic activity of the human gut microbiome- a pilot study

期刊

GUT MICROBES
卷 13, 期 1, 页码 1-20

出版社

TAYLOR & FRANCIS INC
DOI: 10.1080/19490976.2021.1875774

关键词

Vitamins; gut microbiome; dysbiosis; targeted delivery

向作者/读者索取更多资源

Recent research suggests that vitamins, particularly vitamin C, B2, and D, may modulate the human gut microbiome in terms of metabolic activity and bacterial composition. In a study involving human clinical trials and fermentation experiments, vitamin C was found to significantly increase microbial alpha diversity and fecal short-chain fatty acids compared to placebo, indicating a potential role of vitamins in regulating gut microbiota.
An increasing body of evidence has shown that gut microbiota imbalances are linked to diseases. Currently, the possibility of regulating gut microbiota to reverse these perturbations by developing novel therapeutic and preventive strategies is being extensively investigated. The modulatory effect of vitamins on the gut microbiome and related host health benefits remain largely unclear. We investigated the effects of colon-delivered vitamins A, B2, C, D, and E on the gut microbiota using a human clinical study and batch fermentation experiments, in combination with cell models for the assessment of barrier and immune functions. Vitamins C, B2, and D may modulate the human gut microbiome in terms of metabolic activity and bacterial composition. The most distinct effect was that of vitamin C, which significantly increased microbial alpha diversity and fecal short-chain fatty acids compared to the placebo. The remaining vitamins tested showed similar effects on microbial diversity, composition, and/or metabolic activity in vitro, but in varying degrees. Here, we showed that vitamins may modulate the human gut microbiome. Follow-up studies investigating targeted delivery of vitamins to the colon may help clarify the clinical significance of this novel concept for treating and preventing dysbiotic microbiota-related human diseases. Trial registration: ClinicalTrials.gov, NCT03668964. Registered 13 September 2018 - Retrospectively registered,https://clinicaltrials.gov/ct2/show/NCT03668964. .

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据